ASTHMAHALER |
EPPY |
JEXT |
RIDDOFAN |
BRONKAID MIST |
MEDIHALER-EPI |
SUS-PHRINE SULFITE FREE |
ANA-GUARD |
ADREN CO |
EMERADE |
ADRENALINE |
ADRENACLICK |
SYMJEPI |
TWINJECT 0.15 |
GPPE INH SOLN |
AUVI-Q |
ANA-KIT |
EPIPEN JR. |
RYBARVIN |
EPI E Z PEN JR |
SUS-PHRINE |
EPINEPHRINE HCL |
EPIPEN |
EPIPEN E Z PEN |
ANAPHYLACTIC SHOCK DRUG KIT |
NSC-62786 |
EPIPEN JR |
ADRENALIN |
EPINEPHRINE |
ASMA-VYDRIN |
SIMPLENE |
BROVON |
RIDDOBRON |
SOLN MADE TO RYBARVIN FOR |
SUS-PHRINE SULFITE-FREE |
TWINJECT 0.3 |
TWINJECT |
PRIMATENE MIST |
ANAPEN |
LEVO-METHYLAMINOETHANOLCATECHOL |
PRIMATENE |
(R)-(-)-ADNEPHRINE |
LEVOEPINEPHRINE |
(R)-EPINEPHRINE |
(-)-ADRENALINE |
(-)-EPINEPHRINE |
(R)-(-)-EPIRENAMINE |
L-EPINEPHRINE |
(R)-(-)-EPINEPHRINE |
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL |
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL |
(R)-(-)-ADRENALINE |
L-ADRENALINE |
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL |
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL |
(-)-3,4-DIHYDROXY-ALPHA-[2-(METHYLAMINO)ETHYL]BENZYL ALCOHOL |
(R)-4-[1-HYDROXY-2-(METHYLAMINO)ETHYL]-1,2-BENZENEDIOL |
(−)-ADRENALINE |
L-DETHYLAMINOETHANOLCATECHOL |
(R)-ADRENALINE |
(-)-3,4-DIHYDROXY-A-[2-(METHYLAMINO)ETHYL]BENZYL ALCOHOL |
L-1-(3,4-DIHYDROXYPHENYL)-2-METHYLAMINOETHANOL |
R-(-)-EPINEPHRINE |
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL |
4-[(1R)-1-HYDROXY-2-(METHYLAMINO)ETHYL]-1,2-BENZENEDIOL |
(-)-(R)-EPINEPHRINE |
L-EPIRENAMINE |
(R)-(−)-ADRENALINE |
chembl:CHEMBL679 |
rxcui:3992 |
pubchem.compound:5816 |
chemidplus:51-43-4 |
drugbank:00668 |
Drug Categories | bronchodilator agents |
Drug Categories | local hemostatics |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | anestethic |
Drug Class | vasoconstrictor agents |
Drug Class | bronchodilator agents |
Year of Approval | approved before 1982 |
Drug Categories | adrenergic alpha-1 receptor agonists |
Drug Categories | adrenergic alpha-2 receptor agonists |
Drug Categories | adrenergic and dopaminergic agents |
Drug Categories | adrenergic beta-1 receptor agonists |
Drug Categories | adrenergic beta-2 receptor agonists |
Drug Categories | adrenergic beta-3 receptor agonists |
Drug Categories | adrenergics, inhalants |
Drug Categories | agents producing tachycardia |
Drug Categories | agents that produce hypertension |
Drug Categories | alpha-and beta-adrenergic agonists |
Drug Categories | antiglaucoma preparations and miotics |
Drug Categories | benzene derivatives |
Drug Categories | cardiac stimulants excl. cardiac glycosides |
Drug Categories | cardiac therapy |
Drug Categories | catechols |
Drug Categories | comt substrates |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | dental agents |
Drug Categories | drugs for obstructive airway diseases |
Drug Categories | epinephrine and similars |
Drug Categories | nasal preparations |
Drug Categories | oct1 substrates |
Drug Categories | oct2 inhibitors |
Drug Categories | ophthalmologicals |
Drug Categories | phenols |
Drug Categories | stomatological preparations |
Drug Categories | sympathomimetic (adrenergic) agents |
Drug Categories | sympathomimetics in glaucoma therapy |
Drug Categories | sympathomimetics, plain |
agonist (activating) |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Novel drug target | Established target |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Novel drug target | Established target |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Novel drug target | Established target |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
Novel drug target | Established target |
agonist (activating) |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Novel drug target | Established target |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
n/a |
Combination therapy | Articaine,Epinephrine |
51-43-4 | CAS Number |
2% Lidocaine and Epinephrine 1:100,000 Injection USP | Drug Brand |
4% Astracaine Dental With Epinephrine 1:200,000 (0.005mg/ml) | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | vet_approved |
Year of Approval | approved before 1982 |
Drug Class | bronchodilator agents |
Drug Class | vasoconstrictor agents |
Drug Indications | anestethic |
Drug Class | Small Molecule |
FDA Approval | approved |
C473 | NCI drug code |
D04PHC | TTD Drug ID |
CHEMBL679 | ChEMBL Drug ID |